Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | ATR | Q13535 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19032231 | 0.89 | ALDH1A1 (0.58) | ABCG2ATRALDH1A1GAAAAK1 | |
| SCHEMBL31012013 | 0.89 | ALDH1A1 (0.58) | ABCG2ATRALDH1A1GAAAAK1 | |
| SCHEMBL31056956 | 0.87 | ACLY (0.51) | AAK1NPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL15932760 | 0.87 | ACLY (0.51) | AAK1NPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL16257042 | 0.85 | KDM4E (0.51) | KDM4EATRALDH1A1HPGDGAA | |
| SCHEMBL24137826 | 0.84 | AAK1 (0.44) | ABCG2ALDH1A1AAK1NPC1RECQL | |
| SCHEMBL29130760 | 0.84 | CYP17A1 (0.41) | ABCG2KDM4EATRALDH1A1GAA | |
| SCHEMBL29130739 | 0.84 | ATR (0.42) | ABCG2KDM4EATRALDH1A1GAA | |
| SCHEMBL30369702 | 0.83 | AAK1 (0.43) | ABCG2AAK1NPC1RECQLRAB9A | |
| SCHEMBL1519234 | 0.83 | AAK1 (0.49) | HPGDAAK1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2025-09-04 | — | — | US | disclosed |
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12275741-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | BALA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| US-20240368172-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2024-11-07 | — | — | US | disclosed |
| EP-4444300-A2 | INHIBITORS OF MENIN-MLL INTERACTION | Bala Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4444313-A1 | INHIBITORS OF MENIN-MLL INTERACTION | Bala Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-118647378-A | Inhibitors of Mei Nen protein interaction with MLL | 巴拉疗法公司 | 2024-09-13 | — | — | CN | disclosed |
| US-11952381-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| WO-2023107687-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-2614052-B1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL MYERS SQUIBB CO (US) | 2014-12-31 | — | — | EP | disclosed |
| EP-2614052-B1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL MYERS SQUIBB CO (US) | 2014-12-31 | — | — | EP | disclosed |
| EP-2614052-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | Bristol-Myers Squibb Company (US) | 2013-07-17 | — | — | EP | disclosed |
| CN-103201268-A | Novel piperazine analogs as broad-spectrum influenza antivirals | BRISTOL MYERS SQUIBB CO | 2013-07-10 | — | — | CN | disclosed |
| US-8362004-B2 | Piperazine analogs as broad-spectrum influenza antivirals | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362004-B2 | Piperazine analogs as broad-spectrum influenza antivirals | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120238539-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-20 | — | — | US | disclosed |
| US-20120238539-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-20 | — | — | US | disclosed |
| WO-2012033736-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012033736-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238539-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | ZC3HAV1, ZC3HAV1L, HCRTR1 | ABCG2 270/4885KDM4E 3183/4885ATR 3137/4885 |
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, BMI1 | ABCG2 4496/4885KDM4E 136/4885ATR 948/4885 |
| US-12275741-B2 | Cardiac sarcomere inhibitors | TNNI3, MYLK2, TNNT2 | ABCG2 2419/4885KDM4E 2153/4885ATR 3056/4885 |
| US-20240368172-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | ABCG2 2419/4885KDM4E 2153/4885ATR 3056/4885 |
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | ABCG2 2419/4885KDM4E 2153/4885ATR 3056/4885 |
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | MLLT1, MEN1, BMI1 | ABCG2 4496/4885KDM4E 136/4885ATR 948/4885 |
| US-11952381-B2 | Cardiac sarcomere inhibitors | TNNI3, MYLK2, TNNT2 | ABCG2 2419/4885KDM4E 2153/4885ATR 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.